Heart failure

Treatment of severe heart failure

ICOMS FLOWMAKER®, the first fully implantable electrophysiological
Cardiac assist device

  • Guillaume Buc, technical director

  • Sophie Jonquière, Head of Sourcing and Supply Chain

BORDEAUX, France, October 13, 2022–(BUSINESS WIRE)–FineHeart SA, a preclinical medical device company that has developed the ICOMS FLOWMAKER®, a fully implantable cardiac output management system designed to address the unmet needs of patients with severe heart failure, announced today today the appointment of two experienced experts in medical devices to support the next clinical and industrial phases of the company.

We are very proud to welcome two internationally renowned leaders who have both played a major role in the development and manufacture of revolutionary implantable devices. Each of them was captivated by the technological and clinical advances that the ICOMS FLOWMAKER® represents. Their arrival gives us even more confidence as we move towards the First-In-Human implementation of our system, scheduled for 2023. I am also very happy that Sophie Jonquière is joining us, thus promoting the feminization of our management committee, in the respect of our parity objectives. In addition, their arrival strengthens our ability to expand our industrial production capacities as we grow.” said Arnaud Mascarell, CEO & co-founder of FineHeart.

Guillaume Buc, technical director
Before joining FineHeart, Guillaume was Technical and R&D Director at Pixium Vision for more than 9 years. His expertise and passion contributed to the development of the PRIMA retinal implant, which is now in its commercialization phase. Previously, he held several strategic management positions at GE Healthcare in Europe for more than 25 years, before becoming technical director of the interventional cardiology department. Guillaume holds an engineering degree from the Ecole Polytechnique in applied mathematics, and from the Ecole Nationale Supérieure des Télécommunications in Paris in image processing and computer science.

“Few projects in the field of health have as many innovative features as the ICOMS FLOWMAKER®. The scientific and technological breakthroughs achieved, based on the exceptional vision of the founders of FineHeart, are colossal and unprecedented in the field of flow pumps. “cardiac support. I am honored to lead the technical team of this company that is redefining the future of cardiology.” said Guillaume Buc.

Sophie Jonquière, Head of Sourcing and Supply Chain
Sophie is a medical device manufacturing and supply chain specialist. For 15 years, she held various positions at Zimmer Biomet in the orthopedic implants activity, during the industrialization process, then in production and distribution management before directing the manufacturing operations of spinal implants and instruments for the EMEA area. She began her career as a manufacturing process engineer at Hemodia. Sophie Jonquière is an engineer in Materials Science and Engineering from INSA Lyon, and a graduate of IAE Bordeaux in Business Management.

I am delighted to bring my know-how in medical device manufacturing processes to this extremely exciting and ambitious project. The ICOMS FLOWMAKER® has everything to change the lives of patients with severe heart failure, a disease that affects so many people.” said Sophie Jonquiere


The ICOMS FLOWMAKER® is the first completely intraventricular wireless flow accelerator that provides physiological support synchronized with the natural contractions of the heart. It respects the natural blood flow and does not require an aortic bypass. This is the first miniaturized device – barely 10 cm – which adapts to the needs of patients, like a pacemaker, to treat more or less severe patients. It has no external transmission as it is recharged through a wireless transcutaneous energy transfer (TET) system. The device is implanted using a minimally invasive beating-heart procedure, commonly performed by cardiac surgeons, which takes an average of 90 minutes.

About FineHeart

FineHeart is a medical device company developing its innovative product, ICOMS FLOWMAKER®, with the potential to treat 200,000 patients with severe heart failure each year. The first human trials are expected in 2023. FineHeart will initially target the 50,000 most severe patients eligible for cardiac support. Initial estimates put this market segment at over US$5 billion.

Created in 2010, FineHeart is based in Bordeaux and employs nearly 50 people. It is led by a team of internationally renowned cardiac surgeons and electro-physiologists: Dr Stéphane Garrigue, PhD, CSO, co-inventor of ICOMS FLOWMAKER®; Dr. Philippe Ritter, MS, co-inventor of cardiac resynchronization (CRT); and Arnaud Mascarell, CEO of FineHeart. The company holds a portfolio of 72 patents in 18 families.

FineHeart is supported by a large pool of industrial and independent public and private investors: Lauak Group, Doliam, Med-INNOV, FineHeart Founders’ Holding representing national and international private investors, mainly from the cardiology sector, and the European investment Verve Ventures as as well as historical shareholders Irdi, Aquiti, Galia, Broadview Ventures and M Capital. FineHeart also benefits from the financial support of the European Union, Bpifrance, the New Aquitaine Region and the Center Region.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20221013005682/en/


Media Relations
Annie-Florence Loyer
[email protected]
+33 (6) 88 20 35

FineHeart Communications
James Palmer
[email protected]
+33 (0)7 60 92 77 72